New PET tracer aims to reveal hidden heart nerve damage

NCT ID NCT04535193

Ongoing Diagnosis Sponsor: Innervate Radiopharmaceuticals LLC (Formerly: Illumina Radiopharmaceuticals LLC) Source: ClinicalTrials.gov ↗

First seen Jul 02, 2026 · Last updated Jul 02, 2026

Summary

This early-phase trial tests a radioactive imaging agent called 18F-mFBG to see how well it can show the nerves in the heart. Researchers will give the agent to 10 adults—some with heart disease and some without—and take PET scans over time. The goal is to measure how the agent moves through the body and heart, and to see if it can spot areas of nerve damage in people with weak heart pumps.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: 18F-mFBG (a radioactive imaging agent)
What this could lead to: If successful, this could provide a new way to detect and measure nerve damage in the heart, helping doctors diagnose and manage heart disease earlier.
What could go wrong: This is a very early, small study (10 people) focused on imaging, not treatment. The agent may not clearly show nerve damage, or results may not apply to broader populations.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for CARDIOVASCULAR DISEASES are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

cardiovascular disorder heart failure

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

CARDIOVASCULAR DISEASES

Contacts and locations

Locations

Mount Sinai Morningside

New York, New York, 10025, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.